Get the Stockscreener App
4.72
0.21%
-0.01
Lifecore Biomedical Inc stock is traded at $4.72, with a volume of 142.18K.
It is down -0.21% in the last 24 hours and up +2.39% over the past month.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
See More
Previous Close:
$4.73
Open:
$4.67
24h Volume:
142.18K
Relative Volume:
0.75
Market Cap:
$178.67M
Revenue:
$147.12M
Net Income/Loss:
$-33.88M
P/E Ratio:
-9.8231
EPS:
-0.4805
Net Cash Flow:
$-13.62M
1W Performance:
-5.79%
1M Performance:
+2.39%
6M Performance:
-33.33%
1Y Performance:
-36.39%
1-Day Range:
$4.4735
$4.75
1-Week Range:
$4.4735
$5.0022
52-Week Range:
$3.625
$8.9799
Lifecore Biomedical Inc Stock (LFCR) Company Profile
Name
Lifecore Biomedical Inc
Sector
Phone
(952) 368-4300
Address
3515 LYMAN BOULEVARD, CHASKA
Compare LFCR vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
4.72 | 180.56M | 147.12M | -33.88M | -13.62M | -0.4805 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Sep-04-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| May-21-25 | Initiated | William Blair | Outperform |
| Sep-05-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-20-23 | Downgrade | Stephens | Overweight → Equal-Weight |
View All
Lifecore Biomedical Inc Stock (LFCR) Latest News
Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript - AOL.com
Judge approves $3.75 million Lifecore investor settlement - Minnesota Lawyer
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update - marketscreener.com
Lifecore Biomedical, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Discipline and Rules-Based Execution in LFCR Response - Stock Traders Daily
Earnings call transcript: Lifecore Biomedical tops revenue view in Q2 2026 - Investing.com Canada
Lifecore Biomedical (NASDAQ:LFCR) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Transcript : Lifecore Biomedical, Inc., Q2 2026 Earnings Call, Aug 05, 2026 - marketscreener.com
Lifecore Biomedical, Inc. Reaffirms Earnings Guidance for the Calendar Year 2026 - marketscreener.com
Lifecore Biomedical, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Lifecore Biomedical Q2 Earnings Call Highlights - MarketBeat
Lifecore Biomedical, Inc. (LFCR) Q2 FY2026 earnings call transcript - Yahoo Finance
LFCR: Q2 revenue fell 6.2% to $34.2M, but new business wins and guidance reaffirmed - TradingView
Lifecore Biomedical Backs 2026 Adj EBITDA of $20.5M-$25M >LFCR - Moomoo
Lifecore Biomedical Q2 revenue falls to $34.2 million as loss widens - Quiver Quantitative
Lifecore Biomedical 2026: Revenue $34.17M, EPS ($0.19) — 10-Q Summary - TradingView
Lifecore Biomedical: Q2 Earnings Snapshot - marketscreener.com
Lifecore Biomedical (NASDAQ: LFCR) Q2 revenue slips as 2026 guidance reaffirmed - Stock Titan
Press Release: Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update - Moomoo
LFCR: Q2 2026 delivered strong revenue, margin expansion, and robust pipeline growth - TradingView
Lifecore Signs Six New Programs, Including Two Commercial-Stage - Stock Titan
Lifecore Biomedical Q2 FY26 net loss widens to $6.2 million; revenue falls 6.2% to $34.2 million - Bitget
Lifecore Biomedical Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore - TMX Newsfile
Zacks Research Upgrades Lifecore Biomedical (NASDAQ:LFCR) to Hold - MarketBeat
Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026 - GlobeNewswire
Lifecore Sets Aug. 5 Webcast for Second-Quarter Results - Stock Titan
Lifecore Biomedical (LFCR) Tests Resistance After a Modest UptickBull Flag - dars.gov.et
Lifecore Biomedical signs three new customer de... - Pluang
Lifecore Biomedical Signs Three New Customer Agreements - The Manila Times
Lifecore Biomedical Announces Three New Customer Agreements Spanning Late-Stage Regenerative Medicine and Early-Stage Development Programs - Quiver Quantitative
Regenerative Medicine and Device Programs Expand Lifecore’s Pipeline - Stock Titan
Lifecore Biomedical Inc (LFCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lifecore Biomedical Inc (LFCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lifecore Biomedical Inc (LFCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
LFCR|Lifecore Biomedical Inc|Price:4.330|Chg%:-0.100 - TradingKey
Lifecore Biomedical Inc (LFCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lifecore Biomedical (LFCR) Slips 2.26% as Stock Tests Key Support Near $4.11Defined Outcome ETF - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical - The National Law Review
Lifecore Biomedical, Inc. Revenue Breakdown – NASDAQ:LFCR - TradingView
Lifecore Biomedical (LFCR) Pulls Back: Testing Key Support After 2.26% DeclineNegative Gamma - dars.gov.et
Lifecore Biomedical Inc. (LFCR) Q1 2026 Earnings: EPS Misses Estimates by Wide Margin Amid Operational ChallengesBook Value Growth - dars.gov.et
LFCR|Lifecore Biomedical Inc|Price:4.340|Chg%:+0.010 - TradingKey
Lifecore Biomedical (LFCR) Q1 2026 earnings summary - Quartr
Lifecore Biomedical (LFCR) Proxy filing Summary - Quartr
LFCR Deadline: LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit - GuruFocus
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sahm
What Triggered Lifecore Biomedical's Recent Stock Plunge - Kavout | AI
New Lifecore Hire Gets 3,500 Stock Units Vesting in Three Years - Stock Titan
Lifecore Biomedical Inc Stock (LFCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
5.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):